IceCure treats first patient in ChoICE post-marketing study
IceCure Medical announced that the first patient in its ChoICE post-marketing study was treated with ProSense cryoablation at West Cancer Center & Research Institute in Germantown, Tennessee. The study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites and generate real-world data for ProSense's FDA-cleared breast cancer indication. The release contains no reported financial results or financial guidance; participating sites are expected to serve as both study centers and active...
Key takeaways
The first ChoICE Study patient was enrolled and treated at West Cancer Center & Research Institute in Germantown, Tennessee.
Dr. Richard E. Fine, MD, FACS, performed the treatment and is Director of the Breast Surgical Oncology Fellowship Program.
The study evaluates ProSense cryoablation for the local treatment of low-risk breast cancer within the FDA-cleared indication.
The study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites.
Participating sites are expected to serve as both study centers and active commercial sites for eligible patients who do not participate in the study.
The disclosed FDA breast cancer indication covers patients aged 70 years and older with biologically low-risk tumors no larger than 1.5 cm who receive adjuvant endocrine therapy, including patients ineligible for surgery.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow ICCM in real time
Get material earnings, filing, IR, and earnings-call alerts by email.